Sökning: "Orphan drugs"

Visar resultat 1 - 5 av 10 uppsatser innehållade orden Orphan drugs.

  1. 1. Studie av livscykel hos nya läkemedel i Sverige som fick EMA godkännandet mellan 2006 och 2017

    Uppsats för yrkesexamina på grundnivå, Uppsala universitet/Institutionen för farmaci

    Författare :Reem Yacoub; [2022]
    Nyckelord :produktlivscykel; livscykel; introduktionsfas; tillväxtfas; mognadsfas; avtagandefas;

    Sammanfattning : Abstract  Background  All products have a life cycle when they are on the market, including pharmaceutical products as they go through different phases from introduction, growth, maturation, to a declining phase.  Aim  To study the length of time for each phase for drugs approved in Sweden between 2006 and 2017, and to compare the times between the approval years studied and the various types of drugs such as oncology and orphan drugs. LÄS MER

  3. 2. Orphan G-Protein Coupled Receptors : Can we deorphanize the remaining orphans despite all the challenges?

    Kandidat-uppsats, Linköpings universitet/Institutionen för fysik, kemi och biologi

    Författare :Micaela Andersson; [2022]
    Nyckelord :Deorphanization; Heterodimerization; High-throughput screening; Orphan G-protein Coupled receptor; Pseudogenes; Reversed pharmacology;

    Sammanfattning : G-protein coupled receptors (GPCRs) play a key role in a broad range of biological processes by binding to a wide variety of signaling molecules, which have resulted in 34% of all FDA-approved drugs which target GPCRs. The human genome encodes for approximately 800 GPCR members of which about 140 non-olfactory receptors remain orphans with an unknown function and endogenous ligand. LÄS MER

  4. 3. Playing the European Postal Code Lottery? : Analysis of Time to Market of new Drugs on the European Market

    Master-uppsats, Uppsala universitet/Nationalekonomiska institutionen

    Författare :Anna Rumetshofer; [2019]
    Nyckelord :Time to Market; Launch Time; Fixed Effects; Drug Characteristics; Country Characteristics;

    Sammanfattning : This thesis seeks to investigate the vastly varying time to market of newly approved drugs across Europe. Firtsly, I use a country fixed effects model on data of newly approved drugs from 2014 to 2017 from 18 European countries. LÄS MER

  5. 4. What should an Optimal and Fair Introduction Process for Orphan Drugs look like? : Experiences and Views of County Officials and Politicians in Northern Sweden

    Magister-uppsats, Umeå universitet/Epidemiologi och global hälsa

    Författare :Carl Lundberg; [2017]
    Nyckelord :Orphan drugs; introduction; Northern Sweden;

    Sammanfattning : Background: Increasing costs and quantities of orphan drugs within the European market has led to much debate in Sweden on how they should be handled within the existing reimbursement system. Previously, there has been little research looking at local and regional handling of and implications of these issues when it comes to decision-making, financing, and access. LÄS MER

  7. 5. Särläkemedelsbehandling inom EU och Sverige - En rättighet?

    Kandidat-uppsats, Lunds universitet/Institutionen för handelsrätt

    Författare :Marika Rosensohn; [2017]
    Nyckelord :EU-rätt; Internationell rätt; mänskliga rättigheter; rätten till hälsa; särläkemedel; sällsynt diagnos; läkemedelsförmån; TVL; sponsor; svensk förmånslagstiftning; tillgång; tillgänglighet; Law and Political Science;

    Sammanfattning : Within the European Union there is approximately between 5000 to 8000 different rare diseases that affect five to eight percent of the EU population sometime during their lifetime. During the 1990’s the awareness of the problem with lack of medicine production for unusual diseases increased. LÄS MER